modeldoc's profile picture. Wife❤Mum❤️Believer❤Cardiologist❤
Professor/MasterPhysician @EmoryMedicine @EmoryatGrady via @UniIbadan @JohnsHopkinsSPH @MSMEDU @VUMC_heart #TheFaceofCardiology

Modele Ogunniyi, MD, MPH

@modeldoc

Wife❤Mum❤️Believer❤Cardiologist❤ Professor/MasterPhysician @EmoryMedicine @EmoryatGrady via @UniIbadan @JohnsHopkinsSPH @MSMEDU @VUMC_heart #TheFaceofCardiology

مثبتة
modeldoc's tweet image. A new chapter in my academic career begins today! #Professor #Thankful #Grateful #Blessed #ModelProf #Cardiology #TheFaceofCardiology #BlackWomeninMedicine

Thankful to God for this new career milestone #Professor. Humbled to join 0.42% of #black full professors in #medicine Thanks to @emory_heart #ACCFIT for the lovely gift ❤️ Special appreciation to my family, mentors, mentees, sponsors, supporters & my #cardiology tribe🙏🏾#Profat50

modeldoc's tweet image. Thankful to God for this new career milestone #Professor. Humbled to join 0.42% of #black full professors in #medicine Thanks to @emory_heart #ACCFIT for the lovely gift ❤️ Special appreciation to my family, mentors, mentees, sponsors, supporters & my #cardiology tribe🙏🏾#Profat50
modeldoc's tweet image. Thankful to God for this new career milestone #Professor. Humbled to join 0.42% of #black full professors in #medicine Thanks to @emory_heart #ACCFIT for the lovely gift ❤️ Special appreciation to my family, mentors, mentees, sponsors, supporters & my #cardiology tribe🙏🏾#Profat50


Modele Ogunniyi, MD, MPH أعاد

🚨 New in @CircAHA : Maternal CVD and pregnancy-related CV complications are rising sharply over 2 decades across >56K pregnancies across @MassGenBrigham. Pregnancy is a critical window for lifelong heart health! 🔗doi.org/10.1161/CIRCUL… @MGBResearchNews #CardioObstetrics

emilyswlau's tweet image. 🚨 New in @CircAHA : Maternal CVD and pregnancy-related CV complications are rising sharply over 2 decades across >56K pregnancies across @MassGenBrigham. 

Pregnancy is a critical window for lifelong heart health! 

🔗doi.org/10.1161/CIRCUL…

@MGBResearchNews #CardioObstetrics

Modele Ogunniyi, MD, MPH أعاد

Most Updated Global Burden of Cardiovascular Disease now out in @JACCJournals 80% (!) of CV disease burden is attributable to modifiable RFs Top modifiable risks in 2023: ⚠️ High systolic BP ⚠️ Dietary risks ⚠️ High LDL cholesterol ⚠️ Air pollution 🔗 jacc.org/doi/10.1016/j.…

mvaduganathan's tweet image. Most Updated Global Burden of Cardiovascular Disease now out in @JACCJournals 

80% (!) of CV disease burden is attributable to modifiable RFs

Top modifiable risks in 2023:

⚠️ High systolic BP
⚠️ Dietary risks
⚠️ High LDL cholesterol
⚠️ Air pollution

🔗 jacc.org/doi/10.1016/j.…

Modele Ogunniyi, MD, MPH أعاد

Curious about Coaching? Join #AHAWIC for this unique opportunity to learn from master coach, physician, & CEO of Empowering Women Physicians - Dr. Sunny Smith! @PamTaubMD @dranulala @Bweber04 @KTamirisaMD @KhazanieHeart @emilyswlau @SamiaMoraMD @JonPHeart @sunnysmithmd

MonSangh's tweet image. Curious about Coaching?  

Join #AHAWIC for this unique opportunity to learn from master coach, physician, & CEO of Empowering Women Physicians - Dr. Sunny Smith!  

@PamTaubMD @dranulala @Bweber04 @KTamirisaMD @KhazanieHeart @emilyswlau @SamiaMoraMD @JonPHeart @sunnysmithmd

Modele Ogunniyi, MD, MPH أعاد

Calling all IM/Peds residents interested in pursuing a career in cardiology🫀: Apply today to join the next cohort of the ACC IM Program. #ACCIMProgram #FutureofCardiology @simplyonyi @KTamirisaMD @modeldoc @melsulistio @DAkinmolayemi @a_l_bailey @dranulala @MelvinEchols9

Apply today for the #ACCIMProgram ➕ Pediatric Residents Cardiology Mentorship Program and gain access to ACC resources and guidance as you explore a career in #cardiology, like program participant @ujebubechukwu. Due Sept. 14 🔗 bit.ly/3wYVDbZ #ChooseCardiology

ACCinTouch's tweet image. Apply today for the #ACCIMProgram ➕ Pediatric Residents Cardiology Mentorship Program and gain access to ACC resources and guidance as you explore a career in #cardiology, like program participant @ujebubechukwu.

Due Sept. 14 🔗 bit.ly/3wYVDbZ #ChooseCardiology


Modele Ogunniyi, MD, MPH أعاد

The 2025 High Blood Pressure Guideline has been released along with many accompanying articles. Check them all out today! Guideline: ahajrnls.org/4mhhrKg 2025 High Blood Pressure Guideline Journal Hub: ahajrnls.org/45l5Jsh

HyperAHA's tweet image. The 2025 High Blood Pressure Guideline has been released along with many accompanying articles. Check them all out today!
Guideline: ahajrnls.org/4mhhrKg
2025 High Blood Pressure Guideline Journal Hub: ahajrnls.org/45l5Jsh

Modele Ogunniyi, MD, MPH أعاد

Honored to be birthday mates with an icon and my idol, the legendary Dr. Nanette Wenger! Happy birthday #QueenofHearts! 📸: @modeldoc

PobeeMD's tweet image. Honored to be birthday mates with an icon and my idol, the legendary Dr. Nanette Wenger! Happy birthday #QueenofHearts!
📸: @modeldoc

It's always a pleasure to celebrate Dr. @NanetteWenger on her birthday @GradyHealth. Happy 95th Birthday🎉🎊 Thank you for your unwavering mentorship, guidance, sponsorship, and support. May this year bring you as much joy and fulfillment as you have given to all of us♥️

modeldoc's tweet image. It's always a pleasure to celebrate Dr. @NanetteWenger on her birthday @GradyHealth. Happy 95th Birthday🎉🎊 Thank you for your unwavering mentorship, guidance, sponsorship, and support. May this year bring you as much joy and fulfillment as you have given to all of us♥️

Modele Ogunniyi, MD, MPH أعاد

Thrilled to welcome the newest @CardioNerds Academy Class! Can't wait to learn & grow together🫀🤓

Gurleen_Kaur96's tweet image. Thrilled to welcome the newest @CardioNerds Academy Class!

Can't wait to learn & grow together🫀🤓


In our accompanying editorial, "Moving from social context to structural solutions requires that we #identify #assess & #address #socioeconomic #structural #environmental & #psychosocial factors" ➡️ bit.ly/hfequity @AGangavelli @RSteinbergMD @AmberJohnsonMD #healthequity

modeldoc's tweet image. In our accompanying editorial, "Moving from social context to structural solutions requires that we #identify #assess & #address #socioeconomic #structural #environmental & #psychosocial factors" ➡️ bit.ly/hfequity
@AGangavelli @RSteinbergMD @AmberJohnsonMD #healthequity

Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure | JACC jacc.org/doi/10.1016/j.… Dramatic differences in age at incident HF 🏨 by race and ethnicity How much can be explained by social and clinical factors? @HeartDocSadiya @JACCJournals

gcfmd's tweet image. Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure | JACC jacc.org/doi/10.1016/j.…

Dramatic differences in age at incident HF 🏨 by race and ethnicity

How much can be explained by social and clinical factors?

@HeartDocSadiya @JACCJournals


Modele Ogunniyi, MD, MPH أعاد

Registration is open for the 4th Annual Women’s Heart Symposium, hosted by @ChristHospital & @MassGenBrigham! Featuring one of our keynote speakers, Dr. Modele Ogunniyi. @modeldoc @EmoryMedicine Register: eventbrite.com/e/4th-annual-w… @TCHHeart @OdaymeMD

ChristHospital's tweet image. Registration is open for the 4th Annual Women’s Heart Symposium, hosted by @ChristHospital & @MassGenBrigham!

Featuring one of our keynote speakers, Dr. Modele Ogunniyi. @modeldoc @EmoryMedicine 
Register: 
eventbrite.com/e/4th-annual-w… @TCHHeart @OdaymeMD

Modele Ogunniyi, MD, MPH أعاد

🚨 High blood pressure is the leading cause of heart disease, heart attack, stroke – & early death. Support your patients w/ #CardioSmart’s: 📊 Infographic: BP basics + lifestyle tips 📄 Handout: Accurate home monitoring More: bit.ly/4mJQUVJ #hypertension #ESCCongress

ACCinTouch's tweet image. 🚨 High blood pressure is the leading cause of heart disease, heart attack, stroke – & early death.

Support your patients w/ #CardioSmart’s:
📊 Infographic: BP basics + lifestyle tips
📄 Handout: Accurate home monitoring

More: bit.ly/4mJQUVJ #hypertension #ESCCongress
ACCinTouch's tweet image. 🚨 High blood pressure is the leading cause of heart disease, heart attack, stroke – & early death.

Support your patients w/ #CardioSmart’s:
📊 Infographic: BP basics + lifestyle tips
📄 Handout: Accurate home monitoring

More: bit.ly/4mJQUVJ #hypertension #ESCCongress

Modele Ogunniyi, MD, MPH أعاد

4/ In a prespecified meta-analysis of 3 trials (DAPA ACT HF-TIMI 68, EMPULSE, and SOLOIST-WHF), in-hospital initiation of SGTL2i ⬇️the early risk of CV death or worsening HF by 29% (HR 0.71, p = 0.012) & all-cause death by 43% (HF 0.57, p = 0.001)

Gurleen_Kaur96's tweet image. 4/ In a prespecified meta-analysis of 3 trials (DAPA ACT HF-TIMI 68, EMPULSE, and SOLOIST-WHF), in-hospital initiation of SGTL2i ⬇️the early risk of CV death or worsening HF by 29% (HR 0.71, p = 0.012) & all-cause death by 43% (HF 0.57, p = 0.001)

Modele Ogunniyi, MD, MPH أعاد

3/ Primary outcome: In-hospital initiation of dapagliflozin did NOT ⬇️the risk of CV death or worsening HF through 2 months compared w/ placebo (HR 0.86, p = 0.20). Safety: Slight⬆️ in hypotension: 3.6% vs. 2.2% in placebo Worsening kidney function: 5.9% vs. 4.7% in placebo

Gurleen_Kaur96's tweet image. 3/ Primary outcome:
In-hospital initiation of dapagliflozin did NOT ⬇️the risk of CV death or worsening HF through 2 months compared w/ placebo (HR 0.86, p = 0.20).

Safety:
Slight⬆️ in hypotension: 3.6% vs. 2.2% in placebo
Worsening kidney function: 5.9% vs. 4.7% in placebo
Gurleen_Kaur96's tweet image. 3/ Primary outcome:
In-hospital initiation of dapagliflozin did NOT ⬇️the risk of CV death or worsening HF through 2 months compared w/ placebo (HR 0.86, p = 0.20).

Safety:
Slight⬆️ in hypotension: 3.6% vs. 2.2% in placebo
Worsening kidney function: 5.9% vs. 4.7% in placebo
Gurleen_Kaur96's tweet image. 3/ Primary outcome:
In-hospital initiation of dapagliflozin did NOT ⬇️the risk of CV death or worsening HF through 2 months compared w/ placebo (HR 0.86, p = 0.20).

Safety:
Slight⬆️ in hypotension: 3.6% vs. 2.2% in placebo
Worsening kidney function: 5.9% vs. 4.7% in placebo
Gurleen_Kaur96's tweet image. 3/ Primary outcome:
In-hospital initiation of dapagliflozin did NOT ⬇️the risk of CV death or worsening HF through 2 months compared w/ placebo (HR 0.86, p = 0.20).

Safety:
Slight⬆️ in hypotension: 3.6% vs. 2.2% in placebo
Worsening kidney function: 5.9% vs. 4.7% in placebo

Modele Ogunniyi, MD, MPH أعاد

2/ Inclusion criteria: ⭐️Pts hospitalized with a primary diagnosis of HF, including signs & symptoms of fluid overload ⭐️⬆️NT-proBNP/BNP ⭐️Any LVEF 2401 pts were randomized to dapa or placebo w/ stratification based on diagnosis of T2DM & history of HF prior to hospitalization

Gurleen_Kaur96's tweet image. 2/ Inclusion criteria:
⭐️Pts hospitalized with a primary diagnosis of HF, including signs & symptoms of fluid overload
⭐️⬆️NT-proBNP/BNP
⭐️Any LVEF

2401 pts were randomized to dapa or placebo w/ stratification based on diagnosis of T2DM & history of HF prior to hospitalization

Modele Ogunniyi, MD, MPH أعاد

1/ In this #SimPub paper in @CircAHA from #ESCCongress, Berg et al report the findings of the DAPA ACT HF-TIMI 68 trial that investigated the efficacy & safety of in-hospital initiation of dapagliflozin in pts hospitalized for HF Here's a summary🧵 🔗bit.ly/3HyAHEg

Gurleen_Kaur96's tweet image. 1/ In this #SimPub paper in @CircAHA from #ESCCongress, Berg et al report the findings of the DAPA ACT HF-TIMI 68 trial that investigated the efficacy & safety of in-hospital initiation of dapagliflozin in pts hospitalized for HF

Here's a summary🧵

🔗bit.ly/3HyAHEg

Modele Ogunniyi, MD, MPH أعاد

In-hospital initiation of dapagliflozin did not significantly⬇️risk of CV death or worsening HF compared w/ placebo In an accompanying meta-analysis of 3 trials, SGTL2i⬇️the early risk of CV death or worsening HF & all-cause death. ahajournals.org/doi/10.1161/CI…

CircAHA's tweet image. In-hospital initiation of dapagliflozin did not significantly⬇️risk of CV death or worsening HF compared w/ placebo In an accompanying meta-analysis of 3 trials, SGTL2i⬇️the early risk of CV death or worsening HF &  all-cause death.  ahajournals.org/doi/10.1161/CI…

Modele Ogunniyi, MD, MPH أعاد

#ESCCongress LBCT DAPA ACT HF TIMI 68 primary results: In-hospital initiation of SGLT2i reduces high risk of adverse outcomes, including death, in early post-discharge period. @ddberg Manuscript out now in @CircAHA ahajournals.org/doi/10.1161/CI…

TIMIStudyGroup's tweet image. #ESCCongress LBCT DAPA ACT HF TIMI 68 primary results:  In-hospital initiation of SGLT2i reduces high risk of adverse outcomes, including death, in early post-discharge period. @ddberg  Manuscript out now in @CircAHA ahajournals.org/doi/10.1161/CI…

Modele Ogunniyi, MD, MPH أعاد

Nice discussion by @BiykemB noting the short duration of study and also the low event rate likely impacted the nonsignificant finding in DAPA ACT HF #LBCT #DAPAACTHF #ESCCongress @escardio

DrMarthaGulati's tweet image. Nice discussion by @BiykemB noting the short duration of study and also the low event rate likely impacted the nonsignificant finding in DAPA ACT HF
#LBCT #DAPAACTHF #ESCCongress @escardio

Modele Ogunniyi, MD, MPH أعاد

DAPA ACT HF-TIMI 68: Dapagliflozin in Patients Hospitalized for Acute Heart Failure #LBCT #ESCCongress #WCCongress 2025 🫀1:1 RCT of Dapa 🆚 Placebo 🫀34% female, 19% Black 🫀SGLT2i is safe in acute hospitalization but no significant difference in primary outcome of…

DrMarthaGulati's tweet image. DAPA ACT HF-TIMI 68: Dapagliflozin in Patients Hospitalized for Acute Heart Failure
#LBCT #ESCCongress #WCCongress 2025
🫀1:1 RCT of Dapa 🆚 Placebo
🫀34% female, 19% Black
🫀SGLT2i is safe in acute hospitalization but no significant difference in primary outcome of…
DrMarthaGulati's tweet image. DAPA ACT HF-TIMI 68: Dapagliflozin in Patients Hospitalized for Acute Heart Failure
#LBCT #ESCCongress #WCCongress 2025
🫀1:1 RCT of Dapa 🆚 Placebo
🫀34% female, 19% Black
🫀SGLT2i is safe in acute hospitalization but no significant difference in primary outcome of…
DrMarthaGulati's tweet image. DAPA ACT HF-TIMI 68: Dapagliflozin in Patients Hospitalized for Acute Heart Failure
#LBCT #ESCCongress #WCCongress 2025
🫀1:1 RCT of Dapa 🆚 Placebo
🫀34% female, 19% Black
🫀SGLT2i is safe in acute hospitalization but no significant difference in primary outcome of…
DrMarthaGulati's tweet image. DAPA ACT HF-TIMI 68: Dapagliflozin in Patients Hospitalized for Acute Heart Failure
#LBCT #ESCCongress #WCCongress 2025
🫀1:1 RCT of Dapa 🆚 Placebo
🫀34% female, 19% Black
🫀SGLT2i is safe in acute hospitalization but no significant difference in primary outcome of…

Loading...

Something went wrong.


Something went wrong.